ArticleInternational journal of pharmaceutics: X2026
A n-heneicosane solid emulsion as a single-dose subunit vaccine elicits broad and durable immune responses in an aged and a Pox virus model.
Article in International journal of pharmaceutics: X, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
The development of single-dose vaccines capable of inducing durable humoral and cellular immune responses would eliminate the need for additional booster doses, which is particularly important for resource-limited settings or in a pandemic scenario. Here, we report the development of a sustained-release n-heneicosane solid emulsion designed to enhance subunit vaccine immunogenicity after a single administration. Fast- and slow-release emulsions were formulated by varying surfactant content and adding CpG to increase the adjuvant activity. The emulsions were characterized by release kinetics, cytotoxicity, and innate immune activation in dendritic cells. The slow-release formulation demonstrated prolonged antigen release and promoted pro-inflammatory cytokine production without inducing significant cytotoxicity. In vivo, a single subcutaneous immunization with antigen-loaded n-heneicosane emulsions elicited robust and long-lasting antigen-specific antibody responses and cellular immune responses in mice. A Sustained IgG, IgG1 and IgG2c responses was observed for 165 days after a single immunization, while an IFN-γ and IL-2 cellular response in splenocytes was observed after 180 days post-immunization. In an Orthopoxvirus subunit vaccine model, the emulsion platform induced high levels of IgG, IgG1 and IgG2a antibody responses at higher or comparable levels than a prime-boost immunization with the MF-59-like adjuvant Addavax. Finally, strong humoral and cellular responses were also generated following a single immunization in 18-month-old mice, highlighting the potential of this platform to overcome age-associated immune dysfunction. Overall, these findings demonstrate that n-heneicosane emulsions function as an effective single-dose vaccine delivery system capable of promoting durable adaptive immunity across multiple subunit vaccine models and aged groups.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.